Skip to main content

Table 1 Patient and treatment parameters

From: Safety of high-dose-rate stereotactic body radiotherapy

 

N 1

Gender

 Male

48 (57%)

 Female

36 (43%)

Age

 Mean/Median [years]

66/67

 Range [years]

19 - 88

RT localization

 Lung

75 (75%)

 Liver

10 (10%)

 Adrenal gland

6 (6%)

 Lymph node

5 (5%)

 Other site

4 (4%)

Lesions treated

 Primary tumor

25 (25%)

 Metastasis

45 (45%)

 Tumor recurrence

16 (16%)

 Primary tumor/Metastasis

14 (14%)

Prescription dose

 48 Gy/4 fx

19 (19%)

 40 Gy/4 fx

10 (10%)

 35 Gy/5 fx

6 (6%)

 60 Gy/10 fx

5 (5%)

 50 Gy/10 fx

5 (5%)

 Other

55 (55%)

BED

 <100 Gy

66 (66%)

 ≥100 Gy

34 (34%)

GTV size

 Mean [cm3]/Median [cm3]

15.4/6.7

 Range [cm3]

0.60 - 126.7

 <14 cm3

65 (65%)

 ≥14 cm3

35 (35%)

PTV size

 Mean [cm3]/Median [cm3]

58.2/35.2

 Range [cm3]

5.9 - 368.7

Energy

 6 MV

84 (84%)

 10 MV

16 (16%)

Dose rate

 Mean [MU/min.]/Median [MU/min.]

1319/1400

 Range [MU/min]

451 - 2400

  1. N1 = number of patients or lesions if not indicated otherwise. (RT: Radiation Therapy, fx: fractions, BED: Biologically Effective Dose, GTV: Gross Tumor Volume, PTV: Planning Target Volume, MU: Monitor Unit).